Table 5.
Number of additional patients who could be treated with Remsima using the drug cost savings made during the first year after launch of Remsima; combined for switch and naïve patient populations
| RA | AS | CD | UC | PsA | Psoriasis | Total | |
|---|---|---|---|---|---|---|---|
| 10% discount scenario | |||||||
| Germany | 57 | 41 | 352 | 122 | 69 | 33 | 674 |
| UK | 94 | 15 | 197 | 30 | 16 | 19 | 372 |
| Italy | 84 | 50 | 64 | 79 | 79 | 54 | 410 |
| The Netherlands | 32 | 15 | 130 | 66 | 7 | 3 | 253 |
| Belgium | 34 | 17 | 114 | 63 | 14 | 7 | 250 |
| Total | 300 | 139 | 858 | 361 | 186 | 116 | 1960 |
| 20% discount scenario | |||||||
| Germany | 128 | 93 | 792 | 275 | 156 | 74 | 1517 |
| UK | 211 | 35 | 444 | 69 | 37 | 42 | 838 |
| Italy | 189 | 113 | 144 | 178 | 178 | 121 | 924 |
| The Netherlands | 71 | 34 | 293 | 148 | 16 | 7 | 570 |
| Belgium | 77 | 39 | 257 | 142 | 31 | 16 | 562 |
| Total | 676 | 313 | 1,930 | 812 | 419 | 260 | 4410 |
| 30% discount scenario | |||||||
| Germany | 219 | 159 | 1358 | 472 | 268 | 126 | 2602 |
| UK | 362 | 60 | 762 | 117 | 64 | 72 | 1436 |
| Italy | 324 | 195 | 247 | 305 | 306 | 208 | 1583 |
| The Netherlands | 122 | 58 | 503 | 253 | 27 | 12 | 976 |
| Belgium | 132 | 67 | 440 | 244 | 54 | 27 | 964 |
| Total | 1158 | 538 | 3309 | 1392 | 718 | 446 | 7561 |
Numbers of patients have been rounded to the nearest integer
AS ankylosing spondylitis, CD Crohn’s disease, PsA psoriatic arthritis, RA rheumatoid arthritis, UC ulcerative colitis